Search

Our central purpose in this viewpoint is to briefly overview the existing literature on the Belt and Road Initiative (BRI) and argue both how pivotal it is in underlining the experiences of local communities and do so from a gendered perspective. If the BRI is a global project in the making, as many argue, then it is important to appreciate how local people make claims, contest when their claims are ignored, refuted, or misrecognized, and through this understand how gendered notions of citizenship are disrupted and enacted. Therefore, we call for further research that genders the BRI to understand the interconnections along the axes between citizenship, claims and contestations to assess the spatial and temporal changes that a global project, such as the BRI, may bring about. [ABSTRACT FROM AUTHOR]

The article is devoted to the problems of determining the amount of damage in criminal proceedings in Ukraine and their solution. An analysis of the reasons for the ineffectiveness of the existing mechanism in the criminal process, establishing the amount of damage to victims of criminal offenses is carried out. The problems of real compensation for damage caused by a criminal offense are considered. The creation of certain conditions that will contribute to real compensation (compensation) of damage is being discussed, starting directly from the stage of the pre-trial investigation, precisely from the moment of entering information into the EDPR. It is noted that in order to protect the rights and legitimate interests of a person who has been harmed by a criminal offense, the victim status should be granted as soon as possible, namely at the initial stage of the pre-trial investigation. The conducted study of the materials of criminal proceedings, in which it was established that the use in part 2 of Art. 55 of the Criminal Procedure Code of Ukraine of the wording «The rights and responsibilities of the victim arise in a person from the moment of submitting an application to involve him in the proceedings as a victim» is not quite effective, because it allows investigators, inquirers to establish a certain time interval between entering information into the ERDR and issuing a resolution on recognizing a person as a victim. It is noted that when studying the application and establishing the grounds for the qualification of a criminal offense, the authorized person engaged in pre-trial investigation has the duty to collect, systematize and analyze all the information contained in the notification of the criminal offense. The specified information includes information on the nature and extent of damage caused by a criminal offense. It is proven that untimely taking measures to compensate for the damage caused only increases the troubles that already fall on the shoulders of the injured person. It was established that at the moment, officials at the stage of entering information into the EDRD have been given more opportunities to carry out effective activities to establish the nature and extent of damage, and in the future - to take a set of measures aimed at compensating victims of criminal acts. [ABSTRACT FROM AUTHOR]

In the article 'How to be absolutely fair, Part I: the Fairness formula', we presented the first theory of comparative and absolute fairness. Here, we relate the implications of our Fairness formula to economic theories of fair division. Our analysis makes contributions to both philosophy and economics: to the philosophical literature, we add an axiomatic discussion of proportionality and fairness. To the economic literature, we add an appealing normative theory of absolute and comparative fairness that can be used to evaluate axioms and division rules. Also, we provide a novel definition and characterization of the absolute priority rule. [ABSTRACT FROM AUTHOR]

We present the first comprehensive theory of fairness that conceives of fairness as having two dimensions: a comparative and an absolute one. The comparative dimension of fairness has traditionally been the main interest of Broomean fairness theories. It has been analysed as satisfying competing individual claims in proportion to their respective strengths. And yet, many key contributors to Broomean fairness agree that 'absolute' fairness is important as well. We make this concern precise by introducing the Fairness formula and the absolute priority rule and analyse their implications for comparative fairness. [ABSTRACT FROM AUTHOR]

Purpose: This study investigates the combined impact of two packaging cues (i.e. packaging material, recycled content claim) and a price premium on young consumers' product perceptions and choices. Design/methodology/approach: Experimental data were collected online via a questionnaire and a hypothetical choice task completed by 221 young consumers (i.e. 19–25 years). We manipulated two packaging cues for a liquid food product: the packaging material (glass vs plastic) and the presence (vs absence) of a recycled content claim (i.e. 100% recycled). We also manipulated whether a price premium was attached to these packaging variations. Findings: The packaging material and the claim both had a significant influence on young consumers' sustainability perceptions, and these perceptions extended to perceptions of various product attributes (e.g. healthiness, quality). When all products cost the same, participants were more likely to choose a glass bottle (i.e. 81%) than a plastic bottle, and a bottle with the recycled content claim (i.e. 79%) than a bottle without this claim. However, these preferences dropped significantly when a price premium was attached to these packaging variations. Originality/value: While most studies have relied on surveys and qualitative methods to investigate consumers' reactions to sustainable packaging, our research uses an experimental method to assess how packaging impacts young consumers' perceptions and choices. Additionally, by manipulating the presence of a price premium, this study uniquely investigates the impact of such a premium on young consumers' willingness to choose sustainable packaging. [ABSTRACT FROM AUTHOR]

This paper examines how social entrepreneurs construct impact arguments as they begin to assess social impact. We examined the experiences of 68 social entrepreneurs in Chile and discovered that the construction of arguments for the purpose of thinking about and experiencing impact is different than the arguments constructed to establish dialogues around it. We explain this dual argument construction as arguments for worth and arguments for legitimacy. We expand scholarship on argumentation by clarifying social entrepreneurs' efforts to pursue adherence facing competing demands and reinforcing their willingness and ability to engage with social impact assessment. We advance the understanding of social impact assessment in social entrepreneurship across three areas: tensions, accountability and performance and extend Nicholls' general theory by explaining what precedes the discursive space where the assessment of social impact reconciles facticity and validity to establish materiality. [ABSTRACT FROM AUTHOR]

Objective: To analyze the current practice of labeling common food with added strains in China, explore the existing problems, and provide a reference for the management of labeling food that contains edible strains. Methods: Label information for prepackaged foods labeled "live bacteria" "lactic acid bacteria" and "probiotics" (excluding health foods and traditional fermented foods) was collected via online and in-person markets and then organized. Results: A total of 526 samples that met the requirements were examined. 65.24% of products used the term "probiotics" in their labels or promotional language. 91.06% of the samples were labeled with the strain name on the packaging, 49.81% of the samples were labeled with the strain name. In addition, 72.43% of the samples were labeled with a bacterial count, with 95% of the product packaging indicating a bacterial count greater than 106 CFU/g (CFU/mL). Further, 29.28% of the samples used functional claims and related descriptions of similar functional claims in labels or promotional language, and 46.9% of the samples indicated an unsuitable intended audience of the product on the label. Conclusion: There are many types of edible mushroom products added to common food in China, and the positions of the labels and methods for naming mushrooms and the quantities that appear in products greatly differ. Some products incorrectly use the term "probiotics", while other products state claims for improper use. A management system in China for general labeling and for the specific labeling of food that contains "lactic acid bacteria" "probiotics" needs to be standardized.

Introduction: The treatment landscape of small cell lung cancer (SCLC) is evolving. Evidence generated from administrative claims is needed to characterize real-world SCLC patients. However, the current ICD-10 coding system cannot distinguish SCLC from non-small cell lung cancer (NSCLC). We developed and estimated the accuracy of an algorithm to identify SCLC in claims-only databases. Methods: We performed a cross-sectional study of lung cancer patients diagnosed from 2016-2017 using the Surveillance, Epidemiology and End Results (SEER), linked with Medicare database. The analysis included two phases -- data exploration (utilizing a 25% random sample) and data validation (remaining 75% sample). The SEER definition of SCLC and NSCLC were used as the gold standard. Claims-based algorithms were identified and evaluated for their sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). Results: The eligible cohort included 31,912 lung cancer patients. The mean age was 76.3 years, 44.6% were male, with 9.4% having SCLC and 90.6% identified as NSCLC using SEER. The exploration analysis identified potential algorithms based on treatment data. In the validation analysis of 7,438 lung cancer patients who received systemic treatment in the outpatient setting, an etoposide-based algorithm (etoposide use in 180 days following lung cancer diagnosis) to identify SCLC showed: sensitivity 95%, specificity 95%, PPV 82% and NPV 99%. Discussion: An etoposide treatment-based algorithm showed good accuracy in identifying SCLC patients. Such algorithms can facilitate analyses of treatment patterns, outcomes, healthcare resource and costs among treated SCLC patients, thereby bolstering the evidence-base for best patient care. [ABSTRACT FROM AUTHOR]

Background: The post-discharge prognosis of patients with sepsis remains a crucial issue; however, few studies have investigated the relationship between pre-sepsis health status and subsequent prognosis in a large population. This study aimed to examine the effect of the pre-sepsis care needs level on changes in care needs and mortality in patients with sepsis 1 year post-discharge. Methods: This was a population-based retrospective cohort study including twelve municipalities in Japan that participated in the Longevity Improvement & Fair Evidence study between April 2014 and March 2022, with a total of 1,491,608 persons. The pre-hospitalization levels of care needs (baseline) were classified from low to high, as no care needs, support level and care needs level 1, care needs levels 2–3, and care needs levels 4–5 (fully dependent). The outcomes were changes in care needs level and mortality 1 year post-discharge, assessed by baseline care needs level using Cox proportional hazard models. Results: The care needs levels of 17,648 patients analyzed at baseline were as follows: no care needs, 7982 (45.2%); support level and care needs level 1, 3736 (21.2%); care needs levels 2–3, 3089 (17.5%); and care needs levels 4–5, 2841 (16.1%). At 1 year post-discharge, the distribution of care needs were as follows: no care needs, 4791 (27.1%); support level and care needs level 1, 2390 (13.5%); care needs levels 2–3, 2629 (14.9%); care needs levels 4–5, 3373 (19.1%); and death, 4465 (25.3%). Patients with higher levels of care needs exhibited an increased association of all-cause mortality 1 year post-discharge after adjusting for confounders [hazard ratios and 95% confidence intervals: support level and care needs level 1, 1.05 (0.96, 1.15); care needs levels 2–3, 1.46 (1.33, 1.60); and care needs levels 4–5, 1.92 (1.75, 2.10); P for trend < 0.001]. Conclusions: Elevated care needs and mortality were observed in patients with sepsis within 1 year post-discharge. Older patients with sepsis and higher baseline levels of care needs had a high association of all-cause mortality 1 year post-discharge. [ABSTRACT FROM AUTHOR]

Despite growing concerns over the increasing popularity and health impact of commercial foods for infants and toddlers, no nutrition or promotional guidelines currently exist for the United States. In 2022, the WHO Regional Office for Europe published a nutrient and promotion profile model (NPPM) to provide guidance and regulation for commercially produced infant and toddler foods. This study assessed the nutritional and promotional profile of infant and toddler foods (6–36 months of age) collected from the top 10 grocery chains in 2023. Products were assessed against the WHO NPPM nutritional and promotional requirements. The type and number of claims across packaging type were also assessed. Of the 651 products examined, 60% failed to meet the nutritional requirements of the NPPM, and 0% met the promotional requirements. Almost 100% of products had at least 1 claim on-pack that was prohibited under the NPPM, with some products displaying up to 11 prohibited claims. Snack-size packages had the lowest compliance with nutrient requirements. These findings highlight that urgent work is needed to improve the nutritional quality of commercially produced infant and toddler foods in the United States. The high use of prohibited claims also suggests the need to regulate the type and number of claims allowed on-pack. [ABSTRACT FROM AUTHOR]

Introduction: Optimal adherence thresholds can vary across medications and disease states. The objective of the study was to determine the optimal threshold of the proportion of days covered (PDC) for tumor necrosis factor (TNF) inhibitors in patients with rheumatoid arthritis (RA). Methods: Patients with RA initiating self-administered TNF inhibitors were identified using 2012–18 Medicare fee-for-service claims. Time-varying PDC was calculated every day for the preceding 90 days during follow-up. Oral and injected glucocorticoid use, hospitalizations, emergency room (ER) visits, serious infections, and a composite of these were measured as outcomes. Time to first occurrence of each outcome as a function of time-varying PDC for TNF inhibitors was evaluated using Cox regression. Incident/dynamic time-dependent receiver operating characteristic curves and Youden's J index were used to obtain the optimal PDC threshold for outcomes at 365 days. Results: Of the 1190 patients who met the study inclusion criteria, almost 75% (865 patients) experienced at least one of the outcomes. Increasing PDC by 10% was significantly associated with decreased risks of the composite outcome (HR 0.98, 95% CI 0.96–1.00), oral glucocorticoid use (HR 0.93, 95% CI 0.91–0.96), and hospitalization (HR 0.96, 95% CI 0.94–0.99) but an increased risk of ER visits (HR 1.04, 95% 1.01–1.07). Optimal PDC thresholds for the composite outcome, oral glucocorticoid use, and hospitalization were 0.64, 0.59, and 0.56, respectively. Conclusions: Increased PDC was associated with a decreased risk of adverse outcomes, except ER visits. The optimal PDC for TNF inhibitors in Medicare patients with RA based on clinical outcomes was about 60%. Key Points • The optimal proportion of days covered threshold for tumor necrosis factor inhibitors at 365 days based on clinical outcomes was found to be about 60%, which is lower than the traditional 80% used to define adherence. • Increased adherence was associated with decreased risks of oral glucocorticoid use, hospitalization, and the composite outcome. However, it was also associated with an increased risk of emergency room visits. • The mean time-varying 90-day proportion of days covered decreased throughout the study starting 92% at day 1 of follow-up to 62% at day 365. [ABSTRACT FROM AUTHOR]

This study delves into the dynamics of 'Variations' and 'Claims' in construction projects. This study aims to identify, categorize, and devise mitigation strategies for critical types of variations and claims that are aligned with the contract's FIDIC conditions. The research draws on input from construction industry professionals, including contract administrators and project managers, and focuses on the MENA region. The region's extensive adoption of FIDIC standards and the rapidly growing construction sector drive this choice. Data collection encompassed a questionnaire distributed to 80 industry experts, predominantly through interviews focused on countries such as Saudi Arabia, the UAE, Kuwait, and Egypt. Utilizing SPSS-V.25 for statistical analysis, this study uncovers the most prevalent and impactful causes of variations and claims, highlighting the critical need for managerial intervention. A key feature is the integration of scientometric analysis into a quantitative finding. Implementing a k-means clustering analysis is a significant addition to the methodology. The survey had high internal consistency with a Cronbach's alpha of 0.97, and the respondents reported frequent and significant claims such as delayed drawings, ambiguous documents, and client changes. The results showed that effective claims management requires clear communication and balanced contracts, while poor design and contract documentation cause variations and claims. The correlation analysis showed strong positive correlations between claim types and causes. To reduce claims and address these factors, most respondents said the survey could predict and reduce claims. [ABSTRACT FROM AUTHOR]

Selexipag is an oral selective agonist of the prostacyclin receptor approved to treat adults with pulmonary arterial hypertension (PAH). Selexipag is initiated at a dose of 200 μg twice daily (bid) and usually titrated up by 200 μg bid weekly (per label) or more slowly (e.g., every other week in real‐world clinical practice) to the highest tolerated individualized dose (ID) ranging from 200 to 1600 µg bid. In the Phase 3 GRIPHON trial, selexipag delayed disease progression and reduced risk of PAH‐related hospitalization compared with placebo; the effect was consistent across three prespecified ID groups: low (200–400 µg bid), medium (600–1000 µg bid), and high (1200–1600 µg bid). This study evaluated patient outcomes across selexipag dose ranges in real‐world practice. Data were analyzed from 1186 US adult patients with PAH on selexipag from the Komodo closed‐claims database (2015‒2022). Of these, 634 (53.5%) patients completed titration and reached their selexipag ID (43.8% high ID, 29.8% medium ID, 26.3% low ID). Subsequently, 72.4% of patients in the low ID group had dose adjustments compared with 61.9% (medium ID) and 34.5% (high ID; standardized mean difference 0.63). There were no significant differences in patient outcomes, i,e, persistence (time to discontinuation) and risk of all‐cause and PAH‐related hospitalization across ID groups. The findings in this diverse, real‐world population of patients with PAH reinforced an individualized approach to the dosing scheme to maximize benefit‐risk and achieve the highest tolerated dose with selexipag similar to findings from the GRIPHON trial and other studies. [ABSTRACT FROM AUTHOR]

This study assessed the incremental healthcare costs and resource utilization (HRU) associated with generalized myasthenia gravis (gMG), as well as variability in these outcomes among patients with gMG and common comorbidities and acute MG-related events. Adults with gMG and without MG were identified from a large US database (2017–2021). The index date was the first MG diagnosis (gMG cohort) or random date (non-MG cohort). Cohorts were propensity score matched 1:1. The gMG cohort included subgroups of patients with a 12-month pre-index (baseline) cardiometabolic or psychiatric comorbidity, or a post-index MG exacerbation/crisis. Monthly healthcare costs (2021 USD) and HRU were compared post-index between gMG and non-MG cohorts. The gMG and matched non-MG cohorts each contained 2,739 patients. Mean incremental healthcare costs associated with MG were $4,155 (gMG: $5,567; non-MG: $1,411), with differences driven by incremental inpatient costs of $2,166 (gMG: $2,617; non-MG: $452); all p < 0.001. The gMG versus non-MG cohort had 4.36 times more inpatient admissions and 2.26 times more outpatient visits; all p < 0.001. Among patients with gMG in cardiometabolic (n = 1,859), psychiatric (n = 1,308), and exacerbation/crisis (n = 419) subgroups, mean monthly healthcare costs were $6,660, $7,443, and $17,330, respectively. gMG is associated with substantial incremental costs and HRU, with inpatient costs driving the total incremental costs. Costs increased by 20% and 34% among patients with cardiometabolic and psychiatric conditions, respectively, and over three times among those with acute MG-related events. gMG is a complex disease requiring management of comorbidities and treatment options that can prevent acute symptomatic events. Generalized myasthenia gravis (gMG) is a rare long-standing condition that affects the junctions between nerves and muscles, causing them to be weak. In a serious case, the diaphragm – a muscle that helps with breathing – becomes so weak that a patient will need a machine to breathe for them. This is called MG exacerbation or crisis. In this study, we used a large insurance database in the United States to look at how much money healthcare payers paid for gMG patients on average and what healthcare resources patients with gMG used. We compared these findings with patients without gMG. Also, among patients with gMG, we reported these findings specifically for patients who also had heart, blood, or blood vessel disease; patients who had a mental illness; and patients who had MG exacerbation or crisis later on. We found that patients with gMG used $5,567 per month on average ($4,155 more than patients without gMG), mostly from overnight hospital stays. Patients with gMG also had four times more overnight hospital stays and two times more hospital day visits when we compared them to patients without gMG. Patients with gMG and other health conditions used even more money and resources per month. Patients with MG exacerbation or crisis used $17,330 per month on average. Our results showed that gMG led to higher healthcare cost and resource use. In order to reduce cost and resources, doctors also need to control for other health conditions as they treat patients with gMG, and to prevent patients from having MG exacerbation or crisis later on. [ABSTRACT FROM AUTHOR]

Purpose: Delay and disruption claims involve a complex process that often result in disputes, unnecessary expenses and time loss on construction projects. This study aims to review and synthesize the contributions of previous research undertaken in this area and propose future directions for improving the process of delay and disruption claims. Design/methodology/approach: This study adopted a holistic systematic review of literature following Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines. A total of 230 articles were shortlisted related to delay and disruption claims in construction using Scopus and Web of Science databases. Findings: Six research themes were identified and critically reviewed including delay analysis, disruption analysis, claim management, contract administration, dispute resolution and delay and disruption information and records. The systematic review showed that there is a dearth of research on managing the wide-ranging information required for delay and disruption claims, ensuring the transparency and uniformity in delay and disruption claims' information and adopting an end-user's centred research approach for resolving the problems in the process of delay and disruption claims. Practical implications: Complexities in delay and disruption claims are real-world problems faced by industry practitioners. The findings will help the research community and industry practitioners to prioritize their energies toward information management of delay and disruption claims. Originality/value: This study contributes to the body of knowledge in delay and disruption claims by identifying the need for conducting more research on its information requirements and management. Subsequently, it provides an insight on the use of modern technologies such as drones, building information modeling, radio frequency identifiers, blockchain, Bigdata and machine learning, as tools for more structured and efficient attainment of required information in a transparent and consistent manner. It also recommends greater use of design science research approach for delay and disruption claims. This will help to ensure delay and disruption claims are the least complex and less dispute-prone process. [ABSTRACT FROM AUTHOR]

The existence of the insurance company industry in Indonesia is considered very important by the government in overcoming the risks faced by society at any time. Because of this, the government imposes provisions for insurance companies regarding the financial health level requirements for insurance companies, namely by using Risk Based Capital. For insurance companies, premium income, claims and profits are important in the survival of insurance companies. The aim of this research is to determine the effect of premiums, claims and profits on Risk Based Capital. Research was conducted on insurance companies registered on the IDX in 2022-2023. The research sample consisted of 17 insurance companies for 2 years taken by purposive sampling with data completeness criteria during the research period. Data analysis was carried out using Panel Data Regression Analysis. The research results obtained are that there is a positive influence of Premiums on Risk Based Capital, there is a negative influence of Claims on Risk Based Capital and there is a negative influence of Profits on Risk Based Capital. [ABSTRACT FROM AUTHOR]

The article discusses the matter of the right to a clean environment and clean air as a personal interest and the possibility of enforcing judgements issued in this area. The authors of the paper address the controversial issue of the classification of this right, analysing whether it can be considered a personal interest directly associated with a natural person. It is also important to identify the relevant entity representing the defendant in such cases, especially when the defendant is the Treasury. In order to pursue claims on the grounds of violations of the right to clean air, it is necessary to determine the guilt of a specific perpetrator. The paper discusses examples of Polish and European cases where rulings have been made on the matter of the right to a clean environment and clean air. These considerations become the grounds for determining what rulings can be made and whether they can be effectively enforced. [ABSTRACT FROM AUTHOR]

Copyright of Critique of Law: Independent Legal Studies / Krytyka Prawa: Niezalezne Studia nad Prawem is the property of Akademia Leona Kozminskiego and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Science & Technology of Food Industry is the property of Science & Technology of Food Industry Editorial Office and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Advertising texts are the result of intentionally arranged communication that aims to draw the attention of potential customers to a product. In advertising language, every word is precisely chosen with a specific communicative intention. There are no limits to stylistic-linguistic creativity or to originality. The phrases and passages I examine can be considered as samples of creative advertising text composition. These are slogans related to the Corona vaccination campaign launched on 7 December 2021 by the Berlin advertising agency Antoni, in which over 1,000 brands and companies from German-speaking countries participated. In the large-scale campaign, the companies were modelling their common or new brand slogans on the call for vaccination. I analyse the forms of the claims, which are characterised by unique originality not least because of the exclusivity of the campaign itself; they thus possess special features. The creative modus procedendi of the slogan design on three linguistic levels – the phonological, lexical and syntactic – are the focus of my interest. The innovative potential of the selected advertising claims is to be regarded as a fundamental catalyst for an increased reception stimulus as well as an increased consumer attention. Werbetexte sind das Ergebnis von Gestaltungsprozessen, die sich zum Ziel setzen, die potenzielle Kundschaft auf ein Produkt aufmerksam zu machen. In der Werbesprache ist jedes Wort genau gewählt und hat eine konkrete Kommunikationsabsicht. Der stilistisch-sprachlichen Kreativität und Originalität sind kaum Grenzen gesetzt. Im vorliegenden Beitrag wird von der Annahme ausgegangen, dass in der Werbung, die aus appellativen Gründen ständig nach Originalität und somit Auffälligkeit strebt, das Prinzip der Kreativität elementar ist. Sie kommt sowohl auf der Bild- als auch Ton- sowie Sprachebene zum Ausdruck. Als Beispiel für schöpferische Kreationen können in Werbetexten Slogans gelten, die ich untersuche. Konkret handelt es sich um Werbeclaims, die im Zusammenhang mit der am 7. Dezember 2021 von der Berliner Werbeagentur Antoni gestarteten Kampagne zur Corona-Schutzimpfung stehen, an der sich über 1000 Marken und Unternehmen aus deutschsprachigen Ländern beteiligten. In der groß angelegten Aktion modellierten die Firmen ihre gängigen oder neuen Markenslogans kreativ und originell entsprechend Impfaufruf. Mein Beitrag hat zum Ziel, die außergewöhnlichen Slogans, die sich durch Originalität, Idiosynkrasie und Kampagnen-Exklusivität auszeichnen, zu analysieren. Im Mittelpunkt meines Interesses stehen kreative Verfahren der Slogangestaltung auf drei sprachlichen Ebenen – und zwar der phonologischen, lexikalischen und syntaktischen. Das innovative sprachgestalterische Potenzial der untersuchten Werbeclaims wirkt als fundamentaler Katalysator für erhöhten Rezeptionsanreiz und gesteigerte Aufmerksamkeit beim Adressaten. [ABSTRACT FROM AUTHOR]

Abstract Purpose This study aimed to investigate the potential relationships between the use of different section of food label, and healthy and pathological aspects of orthorexia among adults. Methods This cross-sectional study was conducted using an online survey (n = 1326). Inclusion criteria were being 19–64 years and graduated from at least primary school. Pregnant and lactating women were excluded. Data were collected using questionnaire including socio-demographic variables, lifestyle factors, body weight and height, frequency of reading different sections of food label (“always”, “when buying a food for the first time”, “when comparing similar packaged foods”, “rarely”, “never”), food label literacy, and Teruel Orthorexia Scale. Participants were categorized as nutrition facts panel-users, ingredients list-users or claim-users if they read at least one item from the relevant parts. Results The proportions of nutrition facts, ingredients list, and claims sections users were 72.3%, 76.3%, and 79.9%, respectively. Both healthy and pathological aspects of orthorexia were associated with reading food labels. The healthy orthorexia had the strongest association with using the ingredients list (OR 1.76, 95% CI 1.41–2.20), whereas the orthorexia nervosa showed the highest association with using nutrition facts panel (OR 1.48, 95% CI 1.20–1.81). While women, physically active participants and those with higher food label literacy were more likely to use all sections of food labels; older age, having children, and chronic disease increased the likelihood of using claims and ingredients list (p